Michael L. Wang
Impact in
- Pathology and Forensic Medicine top 0.05%
- Lymphoma Diagnosis and Treatment
- Hematology top 0.1%
- Multiple Myeloma Research and Treatments
Papers in
-
- Lymphoma Diagnosis and Treatment 276
- Hematology 105
- Multiple Myeloma Research and Treatments 104
- Co-authors
- Preetesh Jain (39 shared papers)Jorge Enrique Romaguera (76 shared papers)Luis Fayad (61 shared papers)Larry W. Kwak (42 shared papers)David Samuel DiCapua Siegel (15 shared papers)Qing Yi (26 shared papers)Donna M. Weber (38 shared papers)Yucai Wang (19 shared papers)
- Journals
- Blood (197 papers)British Journal of Haematology (32 papers)Blood Advances (20 papers)Journal of Hematology & Oncology (17 papers)Journal of Clinical Oncology (16 papers)
- Partner nations
- United StatesChinaCanada
In The Last Decade
Michael L. Wang
524 papers receiving 29.3k citations
Michael L. Wang's Hit Papers
Peers
Comparison fields: 5 of 100
- Pathology and Forensic Medicine 7.7k
- Hematology 5.7k
- Oncology 6.1k
- Genetics 1.8k
- Immunology 1.5k
Countries citing papers authored by Michael L. Wang
This map shows the geographic impact of Michael L. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Wang more than expected).
Fields of papers citing papers by Michael L. Wang
This network shows the impact of papers produced by Michael L. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Wang. The network helps show where Michael L. Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael L. Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 544 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Hit paper breakdown → | 2020 | 1931 |
| 2 | Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Hit paper breakdown → | 2020 | 1766 |
| 3 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Hit paper breakdown → | 2020 | 1452 |
| 4 | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Hit paper breakdown → | 2013 | 1382 |
| 5 | Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Hit paper breakdown → | 2014 | 1137 |
| 6 | Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America Hit paper breakdown → | 2007 | 1059 |
| 7 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials Hit paper breakdown → | 2019 | 696 |
| 8 | T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma Hit paper breakdown → | 2016 | 679 |
| 9 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study Hit paper breakdown → | 2011 | 655 |
| 10 | A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Hit paper breakdown → | 2012 | 566 |
| 11 | 2005 | 456 | |
| 12 | 2004 | 450 | |
| 13 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Hit paper breakdown → | 2021 | 370 |
| 14 | Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2017 | 360 |
| 15 | Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Hit paper breakdown → | 2015 | 355 |
| 16 | 1999 | 354 | |
| 17 | 2014 | 316 | |
| 18 | 1998 | 271 | |
| 19 | 2009 | 266 | |
| 20 | Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study Hit paper breakdown → | 2022 | 241 |
About Michael L. Wang
Michael L. Wang is a scholar working on Pathology and Forensic Medicine, Hematology, Oncology, Genetics and Immunology, having authored 544 papers that have together received 30.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (276 papers), Multiple Myeloma Research and Treatments (104 papers), CAR-T cell therapy research (47 papers), Chronic Lymphocytic Leukemia Research (24 papers), Immunotherapy and Immune Responses (5 papers), Protein Degradation and Inhibitors (3 papers), Neutropenia and Cancer Infections (3 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (7.7k citations), Hematology (5.7k citations), Oncology (6.1k citations), Genetics (1.8k citations) and Immunology (1.5k citations). Michael L. Wang has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Preetesh Jain, Jorge Enrique Romaguera, Luis Fayad, Larry W. Kwak, David Samuel DiCapua Siegel, Qing Yi, Donna M. Weber, Yucai Wang, Felipe Samaniego and Andre Henri Goy. Their work appears in journals such as Blood, British Journal of Haematology, Blood Advances, Journal of Hematology & Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.